Charles A. McWherter
2018
In 2018, Charles A. McWherter earned a total compensation of $1.8M as Chief Science Officer at Cymabay Therapeutics, a 153% increase compared to previous year.
Compensation breakdown
| Bonus | $170,276 |
|---|---|
| Option Awards | $1,211,685 |
| Salary | $405,418 |
| Other | $4,738 |
| Total | $1,792,117 |
McWherter received $1.2M in option awards, accounting for 68% of the total pay in 2018.
McWherter also received $170.3K in bonus, $405.4K in salary and $4.7K in other compensation.
Rankings
In 2018, Charles A. McWherter's compensation ranked 6,284th out of 14,244 executives tracked by ExecPay. In other words, McWherter earned more than 55.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,284 out of 14,244 | 56th |
Division Manufacturing | 2,410 out of 5,765 | 58th |
Major group Chemicals And Allied Products | 900 out of 2,128 | 58th |
Industry group Drugs | 755 out of 1,817 | 58th |
Industry Pharmaceutical Preparations | 586 out of 1,391 | 58th |
Source: SEC filing on April 26, 2019.
McWherter's colleagues
We found four more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2018.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019